Structure Therapeutics Inc.

$GPCR gapped up today on significant volume after the drug developer’s oral obesity treatment succeeded in a small early-stage study. The drug called GSBR-1290 at the moment is in the same class as Novo Nordisk’s  weight-loss drug Wegovy and Eli Lilly’s diabetes drug Mounjaro. The difference being those two are administered as a weekly injectable, where GSBR-1290 is taken as a daily oral pill.